Cuvitru
Named-patient access overview. Cuvitru is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Cuvitru
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Cuvitru (immune globulin subcutaneous, human, 20% solution) is a ready-to-use subcutaneous immunoglobulin (SCIG) developed by Takeda (originally Baxalta/Shire). The US Food and Drug Administration approved Cuvitru in September 2016 as replacement therapy for primary humoral immunodeficiency (PI) in adult and paediatric patients aged two years and older, including conditions such as common variable immunodeficiency, X-linked agammaglobulinaemia, congenital agammaglobulinaemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Cuvitru is administered subcutaneously, typically once weekly or every two weeks after individualised dose titration, and can be self-administered at home following training. Treatment is supervised by an allergist-immunologist experienced in immunoglobulin replacement therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Cuvitru
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cuvitru is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list immunoglobulin G as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country access guide for Cuvitru in every market we coordinate. Each page below covers the destination-country regulatory pathway, how quotes work, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cuvitru
Submit a 60-second intake. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Cuvitru if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Cuvitru for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Cuvitru through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Cuvitru. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Cuvitru through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Cuvitru to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Cuvitru to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Cuvitru cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Cuvitru?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.